| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| BERNS PAUL L | Title: Chief Executive Officer and Chairman of the Board, Director | C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN | /s/ Michael Milligan, as Attorney-in-Fact for Paul L. Berns | 30 May 2025 | 0001202769 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NMRA | Stock Option (Right to Buy) | Disposed to Issuer | -497,049 | -100% | 0 | 28 May 2025 | Common Stock | 497,049 | $1.69 | Direct | F1, F2 | ||
| transaction | NMRA | Stock Option (Right to Buy) | Disposed to Issuer | -955,864 | -100% | 0 | 28 May 2025 | Common Stock | 955,864 | $1.69 | Direct | F2, F3 | ||
| transaction | NMRA | Stock Option (Right to Buy) | Disposed to Issuer | -342,500 | -100% | 0 | 28 May 2025 | Common Stock | 342,500 | $1.69 | Direct | F2, F4 | ||
| transaction | NMRA | Stock Option (Right to Buy) | Disposed to Issuer | -2,000,000 | -100% | 0 | 28 May 2025 | Common Stock | 2,000,000 | $1.69 | Direct | F2, F5 | ||
| transaction | NMRA | Stock Option (Right to Buy) | Award | +497,049 | 497,049 | 28 May 2025 | Common Stock | 497,049 | $0.7200 | Direct | F1, F2, F6 | |||
| transaction | NMRA | Stock Option (Right to Buy) | Award | +955,864 | 955,864 | 28 May 2025 | Common Stock | 955,864 | $0.7200 | Direct | F2, F3, F6 | |||
| transaction | NMRA | Stock Option (Right to Buy) | Award | +342,500 | 342,500 | 28 May 2025 | Common Stock | 342,500 | $0.7200 | Direct | F2, F4, F6 | |||
| transaction | NMRA | Stock Option (Right to Buy) | Award | +2,000,000 | 2,000,000 | 28 May 2025 | Common Stock | 2,000,000 | $0.7200 | Direct | F2, F5, F6 |
| Id | Content |
|---|---|
| F1 | 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| F2 | On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 6, all other terms of the option remain unchanged. |
| F3 | 25% of the shares subject to the option vest on the first anniversary measured from July 3, 2023 (the "Vesting Commencement Date.), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| F4 | 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| F5 | 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. |
| F6 | On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026. |
Title: Chief Executive Officer and Chairman of the Board